There were no clinically pertinent improvements when compared with 2011 apart from new information and new tips with regard to the treatment with bisphosphonates and denosumab (see segment ‘Bisphosphonates and RANKL Antibody Denosumab’). The advice is partly depending on new evidence ensuing from a systematic evaluation of the Cochrane https://janet987hyl4.vidublog.com/profile